| Expression pattern: |
DN |
| Associated gene: |
ADAM10, ADAMTS4, CD2AP, CDC42SE2, CELF1, CRY2, F5, GALNT7, IL6R, MAPT, MINK1, NFIC, PLEKHA1, SCIMP, SLC24A4, TP53INP1 |
| Associated microRNA: |
hsa-miR-18a-5p, hsa-miR-18b-5p, hsa-miR-149-5p, hsa-miR-30e-5p, hsa-miR-197-5p |
| Biological function: |
Potential plasma biomarker; down-regulated in AD; inferred to impact AD-related pathways and enriched for hippocampus-associated targets; includes AD genes such as ADAM10 and MAPT among predicted target proteins. |
| Molecular mechanism: |
Predicted ceRNA network with miRNA binding predicted by TargetScan/miRanda; downstream targets from miRTarBase/miRWalk with GO/KEGG/Reactome enrichment; enrichment in AD-associated genes. |
| Biological pathway or process: |
ceRNA regulation (other); apoptosis (other); AMPK (other); MAPK (other); PI3K/AKT/mTOR (other); other pathway/process (other) |
| Detected method: |
Q
M
|
| Validation methods: |
Microarray; RNase R Treatment; RT-qPCR; Clinical Sample Validation; ROC Analysis; Bioinformatics Analysis |
| Clinical significance: |
ROC analysis showed good diagnostic accuracy for distinguishing AD from healthy controls (AUC 0.817). |
| Description: |
hsa_circRNA_102619 (NOL10 locus) is reduced in plasma of AD patients vs controls and is supported as a diagnostic biomarker by ROC analysis. Bioinformatic network/enrichment analyses link its predicted miRNA-mediated targets to AD-associated genes (including ADAM10 and MAPT) and AD-relevant pathways. |
| Confidence score: |
0.5963 |